Put your AAV on the Fast-Track to the Clinic
Summary: In this executive summary, Catalent Cell & Gene Therapy experts George Buchman, Ph.D., Research Fellow, and Bhargavi Kondragunta, Ph.D., Director, Internal R&D and Product Development, explain Catalent’s approach to fast-tracking AAVs through a platform approach that is consistent and scalable, along with providing clients with Catalent’s clonal cell-line and off-the-shelf plasmids for a one-stop integrated solution. The authors provide a blueprint for a complete platform approach, enabling a process that easily scales as the project progresses to late-stage GMP production and to market.